ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 0.0 |
| Other income | 7.6 | 0.7 | 0.2 |
| Total income | 7.6 | 0.7 | 0.2 |
| Profit before exceptional items & tax | -56.9 | -31.6 | -0.2 |
| Profit before tax | -56.9 | -31.6 | -0.2 |
| Net profit | -67.9 | 14.3 | -130.1 |
| Operating margin | -748.7% | n/m | -100.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: NECLIFE. Figures extracted from the filing.
Nectar Lifesciences Ltd: key numbers
- Share price
- ₹10.48
- Market cap
- ₹235.0 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹-292.9 Cr
- P/E (TTM)
- -1.0×Sector 43.8×
- Promoter holding
- 51.84%+0.00% QoQ
- FII holding
- 0.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nectar Lifesciences Ltd
All →Nectar Lifesciences Board Meeting Date
NECTAR LIFESCIENCES LIMITED intimated a board meeting on 14 Nov 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. No financial figures are disclosed in this intimation.
Nectar Lifesciences Other Announcement
Nectar Lifesciences Ltd has filed its quarterly shareholding pattern as per SEBI regulations. The document details the promoter group and public shareholding for the quarter.
Nectar Lifesciences Annual General Meeting
Nectar Lifesciences Limited submitted the minutes of its 31st Annual General Meeting held on September 18, 2026. Shareholders approved financial statements and the re-appointment of directors.
Nectar Lifesciences Legal & Regulatory
Nectar Lifesciences provided an update on a material tax litigation where the High Court remanded the matter to the Appellate Authority for fresh consideration.
Nectar Lifesciences Management Change
Nectar Lifesciences Limited has announced the appointment of Dr. Gunmala Suri as a Director. Additionally, three other directors have been re-appointed to the Board.
Nectar Lifesciences Annual General Meeting
Nectar Lifesciences filed proceedings of its 31st AGM held September 18, 2026. Resolutions covered adoption of FY26 financials and director re-appointments.